ClinicalTrials.gg
CompletedNCT01767376Updated Sep 6, 2017Results posted

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age

A Phase 3 interventional study of Meningococcal vaccine GSK134612 and Boostrix® in Infections, Meningococcal, sponsored by GlaxoSmithKline. Completed at 15 sites in 3 countries. Open to participants aged 11 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-06.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
692
Allocation
Randomized
Ages
11 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 71 studies in Meningococcal Infections by GlaxoSmithKline — none open to participants now, 1 under way, none of them phase 3. Meningococcal Infections · GlaxoSmithKline.

Enrollment
33rd of 67
692 · median 613
Started
2013
with 4 others
Phase 3
34 of 71
none open now
Registered
45th of 71
by date

Among the 71 studies in Meningococcal Infections by GlaxoSmithKline, this one is the 33rd largest by enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2013, is one of 34 in phase 3, and was the 45th registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

None of the 71 studies in Meningococcal Infections by GlaxoSmithKline is open now. The open studies under Meningococcal Infections, anywhere →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 11 Years to 25 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 71 studies in Meningococcal Infections by GlaxoSmithKline as a file.
02

Study summary

The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the meningococcal conjugate vaccine (MenACWY-TT) co-administered with Boostrix® versus each of the two vaccines given separately in healthy adolescents and young adults.

03

Conditions studied

  • Infections, Meningococcal

Keywords

  • Young adults
  • Adolescents
  • Reactogenicity
  • Diphtheria
  • pertussis
  • Immunogenicity
  • Tetanus
  • Meningococcal vaccines
  • Safety
  • Neisseria meningitidis
  • Healthy
04

Who can participate

Ages eligible
11 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Subjects and subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • A male or female between, and including, 11 and 25 years of age at the time of the first vaccination.
  • Written obtained from the subject/from the parent(s)/LAR(s) of the subject.
  • Written informed assent obtained from the subjects when applicable according to local regulations.
  • Female subjects of non- may be enrolled in the study.

    • Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy or ovariectomy.
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for two months after completion of the vaccination series.

Exclusion criteria

Exclusion Criteria:

  • Child in care.
  • Use of any or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration of or other immune-modifying drugs within six months prior to the first vaccine dose. For , this will mean prednisone ≥ 10 mg/day, or equivalent. Inhaled and topical steroids are allowed.
  • Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose of vaccine and ending 30 days after the last dose of vaccine, with the exception of licensed inactivated influenza vaccine.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Previous vaccination with a meningococcal vaccine.
  • History of meningococcal disease.
  • Vaccination with a DTP-containing vaccine within the previous five years.
  • History of serious allergic reaction following any other DTP-containing vaccine or any component of the study vaccines.
  • History of encephalopathy within seven days following administration of a previous dose of pertussis vaccine that is not attributable to another identifiable cause.
  • Temperature of ≥ 40.5°C (105°F) within 48 hours of receipt of a previous dose of DTP vaccine, not due to another identifiable cause.
  • Collapse or shock-like state within 48 hours of receipt of a previous dose of DTP vaccine.
  • Seizures with or without fever within three days of a previous dose of DTP vaccine.
  • Severe Arthus-type reactions following a prior dose of tetanus toxoid (TT) within the previous ten years.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination during the study period.
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s).
  • Progressive neurologic disorder, uncontrolled epilepsy or progressive encephalopathy.
  • History of any neurologic disorders or seizures, including Guillain-Barré syndrome (GBS). History of a simple, single febrile seizure is permitted.
  • Bleeding disorders, such as haemophilia or thrombocytopenia, or subjects on anticoagulant therapy.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine, or planned administration during the study period.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions.
  • Family history of congenital or hereditary immunodeficiency.
  • Major congenital defects or serious chronic illness.
  • Acute disease and/or fever at the time of enrolment.

    • Fever is defined as temperature ≥ 37.5°C /99.5°F for oral, axillary or tympanic route.
    • Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
692 participants (actual)

Study arms

  • Experimental
    Nimenrix+ Boostrix Group

    Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Nimenrix vaccine co-administered with one dose of Boostrix vaccine, at Month 0, administered by intramuscular injection into the deltoid muscle.

    Biological: Meningococcal vaccine GSK134612 · Biological: Boostrix®

  • Experimental
    Nimenrix Group

    Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Nimenrix vaccine at Month 0 and one dose of Boostrix vaccine at Month 1. Both vaccines were administered by intramuscular injection into the deltoid muscle.

    Biological: Meningococcal vaccine GSK134612 · Biological: Boostrix®

  • Experimental
    Boostrix Group

    Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Boostrix vaccine at Month 0 and one dose of Nimenrix vaccine at Month 1. Both vaccines were administered by intramuscular injection into the deltoid muscle.

    Biological: Meningococcal vaccine GSK134612 · Biological: Boostrix®

Interventions

  • BiologicalMeningococcal vaccine GSK134612

    One dose administered intramuscularly (IM) in the deltoid muscle of the arm.

    Also known as: MenACWY-TT, Nimenrix

  • BiologicalBoostrix®

    One dose administered intramuscularly (IM) in the deltoid of the right arm (in Co-ad Group) and left arm (in TdapACWY and ACWYTdap Groups).

    Also known as: Tdap

06

What researchers measure

Primary outcomes

  1. Anti-Meningitis Antibody Titers by Serum Bactericidal Assay Using Rabbit Complement (rSBA)

    The analysis was performed for the serogroups -MenA, -MenC -MenW-135 and -MenY. Antibody titers tabulated as geometric mean titers (GMTs), were obtained by serum bactericidal assay using rabbit complement and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL). The primary outcome results only refer to Nimenrix+Boostrix Group and Nimenrix Group.

    Time frame: One month after Nimenrix vaccination (i.e. Month 1 for Nimenrix+Boostrix and Nimenrix Groups and Month 2 for Boostrix Group)

  2. Number of Subjects With Anti-D and Anti-T Concentrations Above the Cut-off Value

    The antibody concentrations were calculated as geometric mean concentrations (GMCs) and expressed as international units per milliliter (IU/mL). The reference cut-off value was an antibody concentration ≥ 1 IU/mL. The primary outcome results only refer to Nimenrix+Boostrix Group and Boostrix Group.

    Time frame: One month after Boostrix vaccination (i.e. Month 1)

  3. Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations

    The antibody concentrations were tabulated as adjusted geometric mean concentrations (GMCs) and expressed as international units per millilitre (IU/mL). The primary outcome results only refer to Nimenrix+Boostrix Group and Boostrix Group

    Time frame: One month after Boostrix vaccination (i.e. Month 1)

Secondary outcomes

  1. Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titres Above the Cut-off Values

    The reference cut-off values of the assay were rSBA-Men antibody concentrations ≥ 1:128 and ≥ 1:8.

    Time frame: Prior to (i.e. Month 0 for Nimenrix+Boostrix and Nimenrix Groups and Month 1 for Boostrix Group) and one month after Nimenrix vaccination (i.e. Month 1 for Nimenrix+Boostrix and Nimenrix Groups and Month 2 for Boostrix Group)

  2. Vaccine Response for rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibodies

    rSBA vaccine response for serogroups A, C, W-135 and Y was defined as: * For initially seronegative subjects (pre-vaccination titer below the cut-off of 1:8): number of subjects with rSBA antibody titers ≥ 1:32 one month after vaccination. * For initially seropositive subjects (pre-vaccination titer ≥ 1:8): number of subjects with rSBA antibody titers at least four times the pre-vaccination antibody titers, one month after vaccination.

    Time frame: One month after Nimenrix vaccination (i.e. Month 1 for Nimenrix+Boostrix and Nimenrix Groups and Month 2 for Boostrix Group)

  3. Anti-D Antibody Concentrations

    The antibody concentrations were tabulated as geometric mean concentrations (GMCs) and expressed as international units per milliliter (IU/mL).

    Time frame: Prior to (PRE i.e. Month 0 for Nimenrix + Boostrix Group and Boostrix Group and Month 1 for Nimenrix Group) and one month after Boostrix vaccination (POST i.e. Month 1 for Nimenrix + Boostrix Group and Boostrix Group and Month 2 for Nimenrix Group)

  4. Anti-T Antibody Concentrations

    The antibody concentrations were tabulated as geometric mean concentrations (GMCs) and expressed as international units per milliliter (IU/mL).

    Time frame: Prior to (i.e. Month 0 for Nimenrix + Boostrix Group and Boostrix Group and Month 1 for Nimenrix Group), one month after Nimenrix vaccination and one month after Boostrix vaccination

  5. Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations Above the Cut-off Value

    The reference cut-off value of the assay was an antibody concentration ≥ 5.0 ELISA units per milliliter (EL.U/mL)

    Time frame: Prior to (i.e. Month 0 for Nimenrix + Boostrix Group and Boostrix Group and Month 1 for Nimenrix Group) and one month after Boostrix vaccination (i.e. Month 1 for Nimenrix + Boostrix Group and Boostrix Group and Month 2 for Nimenrix Group)

  6. Booster Responses for Anti-PT, Anti-FHA and Anti-PRN Concentrations

    Booster response to the pertussis components is defined as: * For initially seronegative subjects, antibody concentration ≥ 4\*cut_off (IU/mL) at one month post-vaccination; * For initially seropositive subjects with pre-vaccination antibody concentration \< 4\*cut_off (IU/mL) : antibody concentration at one month post-vaccination ≥ 4 fold the pre-vaccination antibody concentration; * For initially seropositive subjects with pre-vaccination antibody concentration ≥ 4\*cut_off (IU/mL) : antibody concentration at one month post-vaccination ≥ 2 fold the pre-vaccination antibody concentration.

    Time frame: One month after Boostrix vaccination (i.e. Month 1 for Nimenrix + Boostrix Group and Boostrix Group and Month 2 for Nimenrix Group)

  7. Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. Results are presented across doses, after each vaccination (with Nimenrix, Boostrix, total).

    Time frame: During the 4-day (Days 0-3) following each vaccination

  8. Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms

    Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination. Results are presented across doses.

    Time frame: During the 4-day (Days 0-3) period following each vaccination

  9. Number of Subjects With New Onset of Chronic Diseases (NOCDs)

    NOCDs include autoimmune disorders, asthma, type I diabetes, allergies.

    Time frame: Throughout the study (Month 0 up to Month 2)

  10. Number of Subjects With Unsolicited Adverse Events AE(s)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: During the 31-day (Days 0-30) post-vaccination period

  11. Number of Subjects With Serious Adverse Events SAE(s)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: Throughout the study (Month 0 up to Month 2)

07

Results

Posted Sep 6, 2017
Limitations and caveats
Due to late availability of the serology results, only safety results were posted by the initial due date.

Participant flow

Participant flow — Overall Study
MilestoneNimenrix+ Boostrix GroupNimenrix GroupBoostrix Group
Started231228232
Completed227225232
Not completed430
Withdrew: Lost to follow-up320
Withdrew: Withdrawal by subject110

Outcome measures

PrimaryAnti-Meningitis Antibody Titers by Serum Bactericidal Assay Using Rabbit Complement (rSBA)

The analysis was performed for the serogroups -MenA, -MenC -MenW-135 and -MenY. Antibody titers tabulated as geometric mean titers (GMTs), were obtained by serum bactericidal assay using rabbit complement and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL). The primary outcome results only refer to Nimenrix+Boostrix Group and Nimenrix Group.

Time frame:
One month after Nimenrix vaccination (i.e. Month 1 for Nimenrix+Boostrix and Nimenrix Groups and Month 2 for Boostrix Group)
Reported as:
Geometric mean · EL.U/mL
Anti-Meningitis Antibody Titers by Serum Bactericidal Assay Using Rabbit Complement (rSBA)
EL.U/mLNimenrix + Boostrix GroupNimenrix GroupBoostrix Group
rSBA-MenA3415.3 (2917.8 to 3997.6)2860.4 (2478.6 to 3300.9)1577.4 (1354.4 to 1837.1)
rSBA-MenC5092.5 (4268.7 to 6075.3)4597.6 (3703.1 to 5708.2)1912.6 (1593.9 to 2295.1)
rSBA-MenW-1359608.5 (8522.5 to 10832.8)9052.8 (7510.3 to 10912.0)3164.6 (2534.0 to 3952.1)
rSBA-MenY7775.8 (6862.3 to 8811.0)6032.6 (5025.7 to 7241.2)4134.4 (3582.3 to 4771.5)
Statistical analysis
  • Nimenrix + Boostrix Group vs Nimenrix Group · ANCOVA · Adjusted gmt ratio: 1.19 · 95% CI 0.97 to 1.48
  • Nimenrix + Boostrix Group vs Nimenrix Group · ANCOVA · Adjusted gmt ratio: 1.12 · 95% CI 0.85 to 1.47
  • Nimenrix + Boostrix Group vs Nimenrix Group · ANCOVA · Adjusted gmt ratio: 1.06 · 95% CI 0.86 to 1.32
  • Nimenrix + Boostrix Group vs Nimenrix Group · ANCOVA · Adjusted gmt ratio: 1.27 · 95% CI 1.02 to 1.59
PrimaryNumber of Subjects With Anti-D and Anti-T Concentrations Above the Cut-off Value

The antibody concentrations were calculated as geometric mean concentrations (GMCs) and expressed as international units per milliliter (IU/mL). The reference cut-off value was an antibody concentration ≥ 1 IU/mL. The primary outcome results only refer to Nimenrix+Boostrix Group and Boostrix Group.

Time frame:
One month after Boostrix vaccination (i.e. Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-D and Anti-T Concentrations Above the Cut-off Value
ParticipantsNimenrix + Boostrix GroupBoostrix Group
Anti-D200203
Anti-T224223
Statistical analysis
  • Nimenrix + Boostrix Group vs Boostrix Group · Difference in percentage: -2.14 · 95% CI -7.88 to 3.53
  • Nimenrix + Boostrix Group vs Boostrix Group · Difference in percentage: -0.44 · 95% CI -2.48 to 1.26
PrimaryAnti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations

The antibody concentrations were tabulated as adjusted geometric mean concentrations (GMCs) and expressed as international units per millilitre (IU/mL). The primary outcome results only refer to Nimenrix+Boostrix Group and Boostrix Group

Time frame:
One month after Boostrix vaccination (i.e. Month 1)
Reported as:
Geometric mean · IU/mL
Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations
IU/mLNimenrix + Boostrix GroupBoostrix Group
Anti-PT53.6 (47.2 to 60.8)68.0 (59.9 to 77.3)
Anti-FHA316.9 (288.0 to 348.6)545.0 (493.2 to 602.4)
Anti-PRN348.3 (293.8 to 412.9)499.0 (419.4 to 593.6)
Statistical analysis
  • Nimenrix + Boostrix Group vs Boostrix Group · ANCOVA · Adjusted gmc ratio: 0.76 · 95% CI 0.66 to 0.89
  • Nimenrix + Boostrix Group vs Boostrix Group · ANCOVA · Adjusted gmc ratio: 0.57 · 95% CI 0.50 to 0.65
  • Nimenrix + Boostrix Group vs Boostrix Group · ANCOVA · Adjusted gmc ratio: 0.72 · 95% CI 0.59 to 0.88
SecondaryNumber of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titres Above the Cut-off Values

The reference cut-off values of the assay were rSBA-Men antibody concentrations ≥ 1:128 and ≥ 1:8.

Time frame:
Prior to (i.e. Month 0 for Nimenrix+Boostrix and Nimenrix Groups and Month 1 for Boostrix Group) and one month after Nimenrix vaccination (i.e. Month 1 for Nimenrix+Boostrix and Nimenrix Groups and Month 2 for Boostrix Group)
Reported as:
Count of participants · Participants
Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titres Above the Cut-off Values
ParticipantsNimenrix + Boostrix GroupNimenrix GroupBoostrix Group
rSBA-MenA ≥ 1:128484633
rSBA-MenC ≥ 1:128224220220
rSBA-MenW-135 ≥ 1:128133330
rSBA-MenY ≥ 1:128225218220
rSBA-MenA ≥ 1:8312923
rSBA-MenC ≥ 1:8226220216
rSBA-MenW-135 ≥ 1:8805670
rSBA-MenY ≥ 1:8226219222
SecondaryVaccine Response for rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibodies

rSBA vaccine response for serogroups A, C, W-135 and Y was defined as: * For initially seronegative subjects (pre-vaccination titer below the cut-off of 1:8): number of subjects with rSBA antibody titers ≥ 1:32 one month after vaccination. * For initially seropositive subjects (pre-vaccination titer ≥ 1:8): number of subjects with rSBA antibody titers at least four times the pre-vaccination antibody titers, one month after vaccination.

Time frame:
One month after Nimenrix vaccination (i.e. Month 1 for Nimenrix+Boostrix and Nimenrix Groups and Month 2 for Boostrix Group)
Reported as:
Count of participants · Participants
Vaccine Response for rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibodies
ParticipantsNimenrix + Boostrix GroupNimenrix GroupBoostrix Group
rSBA-MenA217207214
rSBA-MenC225210215
rSBA-MenW-135225216211
rSBA-MenY220214212
SecondaryAnti-D Antibody Concentrations

The antibody concentrations were tabulated as geometric mean concentrations (GMCs) and expressed as international units per milliliter (IU/mL).

Time frame:
Prior to (PRE i.e. Month 0 for Nimenrix + Boostrix Group and Boostrix Group and Month 1 for Nimenrix Group) and one month after Boostrix vaccination (POST i.e. Month 1 for Nimenrix + Boostrix Group and Boostrix Group and Month 2 for Nimenrix Group)
Reported as:
Geometric mean · IU/mL
Anti-D Antibody Concentrations
IU/mLNimenrix + Boostrix GroupNimenrix GroupBoostrix Group
Anti-D, PRE0.3 (0.3 to 0.4)0.3 (0.3 to 0.4)0.3 (0.3 to 0.4)
Anti-D, POST4.0 (3.4 to 4.6)4.6 (3.9 to 5.4)4.7 (4.0 to 5.4)
SecondaryAnti-T Antibody Concentrations

The antibody concentrations were tabulated as geometric mean concentrations (GMCs) and expressed as international units per milliliter (IU/mL).

Time frame:
Prior to (i.e. Month 0 for Nimenrix + Boostrix Group and Boostrix Group and Month 1 for Nimenrix Group), one month after Nimenrix vaccination and one month after Boostrix vaccination
Reported as:
Geometric mean · IU/mL
Anti-T Antibody Concentrations
IU/mLNimenrix + Boostrix GroupNimenrix GroupBoostrix Group
Anti-T, pre-vaccination0.6 (0.5 to 0.8)0.6 (0.5 to 0.7)0.7 (0.5 to 0.8)
Anti-T, Month 123.5 (20.8 to 26.5)18.5 (16.0 to 21.3)13.5 (12.3 to 14.8)
Anti-T, Month 2—13.0 (11.7 to 14.5)16.3 (14.6 to 18.2)
SecondaryNumber of Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations Above the Cut-off Value

The reference cut-off value of the assay was an antibody concentration ≥ 5.0 ELISA units per milliliter (EL.U/mL)

Time frame:
Prior to (i.e. Month 0 for Nimenrix + Boostrix Group and Boostrix Group and Month 1 for Nimenrix Group) and one month after Boostrix vaccination (i.e. Month 1 for Nimenrix + Boostrix Group and Boostrix Group and Month 2 for Nimenrix Group)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations Above the Cut-off Value
ParticipantsNimenri+ Boostrix GroupNimenrix GroupBoostrix Group
Anti-PT, PRE162156153
Anti-PT, Month 1/Month 2221220223
Anti-FHA, PRE222221220
Anti-FHA, Month 1/Month 2225220223
Anti-PRN, PRE200200207
Anti-PRN, Month 1/Month 2223218221
SecondaryBooster Responses for Anti-PT, Anti-FHA and Anti-PRN Concentrations

Booster response to the pertussis components is defined as: * For initially seronegative subjects, antibody concentration ≥ 4\*cut_off (IU/mL) at one month post-vaccination; * For initially seropositive subjects with pre-vaccination antibody concentration \< 4\*cut_off (IU/mL) : antibody concentration at one month post-vaccination ≥ 4 fold the pre-vaccination antibody concentration; * For initially seropositive subjects with pre-vaccination antibody concentration ≥ 4\*cut_off (IU/mL) : antibody concentration at one month post-vaccination ≥ 2 fold the pre-vaccination antibody concentration.

Time frame:
One month after Boostrix vaccination (i.e. Month 1 for Nimenrix + Boostrix Group and Boostrix Group and Month 2 for Nimenrix Group)
Reported as:
Count of participants · Participants
Booster Responses for Anti-PT, Anti-FHA and Anti-PRN Concentrations
ParticipantsNimenrix + Boostrix GroupNimenrix GroupBoostrix Group
Anti-PT antibody (assay cut-off=2.693 IU/mL)201188201
Anti-FHA antibody (assay cut-off=2.046 IU/mL)208210213
Anti-PRN antibody (assay cut-off=2.187 IU/mL)209198207
SecondaryNumber of Subjects Reporting Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. Results are presented across doses, after each vaccination (with Nimenrix, Boostrix, total).

Time frame:
During the 4-day (Days 0-3) following each vaccination
Reported as:
Count of participants · Participants
Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms
ParticipantsNimenrix + Boostrix GroupNimenrix GroupBoostrix Group
Any Pain, Total176148167
Grade 3 Pain, Total15198
Any Redness, Total817576
Grade 3 Redness, Total4106
Any Swelling, Total717168
Grade 3 Swelling, Total597
Any Pain, post-Nimenrix155121156
Grade 3 Pain, post-Nimenrix13128
Any Redness, post-Nimenrix645665
Grade 3 Redness, post-Nimenrix355
Any Swelling, post-Nimenrix575154
Grade 3 Swelling, post-Nimenrix347
Any Pain, post-Boostrix12110192
Grade 3 Pain, post-Boostrix780
Any Redness, post-Boostrix615439
Grade 3 Redness, post-Boostrix164
Any Swelling, post-Boostrix484733
Grade 3 Swelling, post-Boostrix351
SecondaryNumber of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination. Results are presented across doses.

Time frame:
During the 4-day (Days 0-3) period following each vaccination
Reported as:
Count of participants · Participants
Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms
ParticipantsNimenrix + Boostrix GroupNimenrix GroupBoostrix Group
Any Fatigue757781
Grade 3 Fatigue254
Related Fatigue706770
Any Gastrointestinal symptoms233125
Grade 3 Gastrointestinal symptoms221
Related Gastrointestinal symptoms202518
Any Headache517665
Grade 3 Headache252
Related Headache496753
Any Temperature141711
Grade 3 Temperature000
Related Temperature10159
SecondaryNumber of Subjects With New Onset of Chronic Diseases (NOCDs)

NOCDs include autoimmune disorders, asthma, type I diabetes, allergies.

Time frame:
Throughout the study (Month 0 up to Month 2)
Reported as:
Count of participants · Participants
Number of Subjects With New Onset of Chronic Diseases (NOCDs)
ParticipantsNimenrix + Boostrix GroupNimenrix GroupBoostrix Group
Number of Subjects With New Onset of Chronic Diseases (NOCDs)153
SecondaryNumber of Subjects With Unsolicited Adverse Events AE(s)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
During the 31-day (Days 0-30) post-vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Unsolicited Adverse Events AE(s)
ParticipantsNimenrix + Boostrix GroupNimenrix GroupBoostrix Group
Number of Subjects With Unsolicited Adverse Events AE(s)364458
SecondaryNumber of Subjects With Serious Adverse Events SAE(s)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
Throughout the study (Month 0 up to Month 2)
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events SAE(s)
ParticipantsNimenrix + Boostrix GroupNimenrix GroupBoostrix Group
Number of Subjects With Serious Adverse Events SAE(s)003

Adverse events

Collected over Solicited local and general symptoms: during the 4-day (Days 0-3) period following each vaccination; Unsolicited AEs: during the 31-day (Days 0-30) post-vaccination period; SAEs: throughout the study (Month 0 - Month 2).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nimenrix+ Boostrix Group0/231 (0%)0/231 (0%)190/231 (82.3%)
Nimenrix Group0/228 (0%)0/228 (0%)166/228 (72.8%)
Boostrix Group0/232 (0%)3/232 (1.3%)180/232 (77.6%)
Most frequent serious events
Most frequent serious events
EventNimenrix+ Boostrix GroupNimenrix GroupBoostrix Group
GastroenteritisInfections and infestations0/2310/2281/232
Orthostatic intoleranceNervous system disorders0/2310/2281/232
DepressionPsychiatric disorders0/2310/2281/232
Most frequent other events
Most frequent other events
EventNimenrix+ Boostrix GroupNimenrix GroupBoostrix Group
PainGeneral disorders176/231148/228167/232
ErythemaSkin and subcutaneous tissue disorders81/23175/22876/232
FatigueGeneral disorders75/23177/22881/232
HeadacheNervous system disorders54/23178/22867/232
SwellingGeneral disorders71/23171/22868/232
Gastrointestinal disorderGastrointestinal disorders23/23131/22825/232
PyrexiaGeneral disorders15/23117/22811/232
NasopharyngitisInfections and infestations6/2318/22815/232

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Nimenrix+ Boostrix GroupNimenrix GroupBoostrix GroupTotal
Mean18.1 ± 4.218.2 ± 4.518.3 ± 4.418.2 ± 4.4
Sex: Female, Male
Sex: Female, Male(Participants)Nimenrix+ Boostrix GroupNimenrix GroupBoostrix GroupTotal
Female128126146400
Male10310286291
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nimenrix+ Boostrix GroupNimenrix GroupBoostrix GroupTotal
Ethnicity — Asian - East Asian Heritage111109111331
Ethnicity — Asian - South East Asian Heritage0011
Ethnicity — White - Caucasian / European Heritage606061181
Ethnicity — Other605959178
08

Study locations

15 sites
  • GSK Investigational Site
    Santo Domingo, Distrito Nacional, Dominican Republic
  • GSK Investigational Site
    Kehl, Baden-Wuerttemberg 77694, Germany
  • GSK Investigational Site
    Tuttlingen, Baden-Wuerttemberg 78532, Germany
  • GSK Investigational Site
    Bindlach, Bayern 95463, Germany
  • GSK Investigational Site
    Wuerzburg, Bayern 97070, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45359, Germany
  • GSK Investigational Site
    Goch, Nordrhein-Westfalen 47574, Germany
  • GSK Investigational Site
    Frankenthal, Rheinland-Pfalz 67227, Germany
  • GSK Investigational Site
    Ansan, 425-707, Korea, Republic of
  • GSK Investigational Site
    Incheon, 400 711, Korea, Republic of
  • GSK Investigational Site
    Incheon, 700-711, Korea, Republic of
  • GSK Investigational Site
    Jeonju Jeonbuk, 561-712, Korea, Republic of
  • GSK Investigational Site
    Seoul, 130-702, Korea, Republic of
  • GSK Investigational Site
    Seoul, 150-950, Korea, Republic of
  • GSK Investigational Site
    Seoul, 158-710, Korea, Republic of
09

References and documents

Publications

  • Rivera L, Schwarz TF, Kim KH, Kim YK, Behre U, Cha SH, Jo DS, Lee J, Lee JS, Cheuvart B, Jastorff A, Van der Wielen M. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study. Vaccine. 2018 Jul 25;36(31):4750-4758. doi: 10.1016/j.vaccine.2018.04.034. Epub 2018 Jun 28. PubMed 29960800 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in Jan 2014, 12 months.

Results were first posted in Sep 2017, 3 years 7 months after primary completion. A results delay was requested in May 2014.

Of 46 industry-sponsored phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 12 months is below that.

Counting every sponsor, half of 46 studies reached it within 15 months; a quarter within 8 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2012
First posted
Jan 14, 2013
StartActual
Jan 10, 2013
Primary completionActual
Jan 16, 2014
CompletionActual
Jan 16, 2014
Results delay requested
May 29, 2014
Results first posted
Sep 6, 2017
Last update
Sep 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01767376
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 14, 2013
Start date
Jan 10, 2013
Primary completion
Jan 16, 2014
Completion
Jan 16, 2014
Results posted
Sep 6, 2017
Last update
Sep 6, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Boostrix

Start the discussion